{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/67105af848726944170ab1fe/6afca113da978fb0901f14b2?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Jagesh Shah: Are Nonviral Gene Therapies Really Safer Than AAVs?","description":"<p>Genetic medicines hold enormous promise, but delivering them safely and precisely to the right cells remains a major challenge. In this episode of <em>Behind the Breakthroughs</em>, Mirai Bio&#39;s chief scientific officer, Jagesh Shah, PhD, discusses advances in targeted lipid nanoparticle delivery, the safety trade-offs between viral and nonviral approaches, and whether nonviral technologies could eventually replace viral vectors.</p><p><br></p><p>Produced and hosted by Jonathan D. Grinstein, PhD</p><p>Audio mixed and mastered by Erick Ziegler</p><p>Brought to you by Inside Precision Medicine (SAGE Publishing)</p>","author_name":"Inside Precision Medicine"}